유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - kyrningahvítblæði, mergbreytilegt, langvinnt, bcr-abl jákvætt - Æxlishemjandi lyf - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - Æxlishemjandi lyf - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 10 mg/16 klst.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 15 mg/16 klst.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

mcneil denmark aps - nicotinum - forðaplástur - 25 mg/16 klst.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

sanofi b.v. - thyrotropin alfa - skjaldkirtilsæxli - fremri sterum stærra hormón og hliðstæðum, sterum og undirstúku hormón og hliðstæðum - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

merck europe b.v.  - interferón beta-1a - margvísleg sclerosis - Ónæmisörvandi, - rebif er ætlað fyrir meðferð:sjúklingar með einum afmýlandi atburði með virkan æsandi ferli, ef val sjúkdómsgreiningar hafa verið útilokað, og ef þeir eru ákveðnir í að vera í mikilli hættu að fá læknisfræðilega ákveðinn heila-og mænusigg, sjúklingum við köstum heila-og mænusigg. Í klínískum rannsóknum, þetta einkenndist af tveimur eða meira bráð tilvikum í síðustu tveimur árum. verkun hefur ekki verið sýnt fram í sjúklinga með efri framsækið heila-og mænusigg án gangi bakslag virkni.

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab - metronidazolum inn - innrennslislyf, lausn - 5 mg/ml

아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - oxycodonum hýdróklóríð - stungulyfs-/innrennslisþykkni, lausn - 10 mg/ml

유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

life molecular imaging gmbh - florbetaben (18f) - radionuclide imaging; alzheimer disease - greining geislavirkja - Þetta lyf er eingöngu ætlað til greiningar. neuraceq er radiopharmaceutical fram í sneiðmyndatöku losun höfði (gÆludÝr) hugsanlegur beta amyloid neuritic sýklum þéttleika í heila fullorðinn sjúklinga með vitsmunalegum skert sem eru metin fyrir alzheimer (ad) og aðrar ástæður vitsmunalegum skert. neuraceq ætti að vera notuð í tengslum við mat klínískum. neikvæð skanna sýnir dreifður eða enginn skellum, sem er ekki í samræmi við greiningu á ad.